Pharmaceutical and veterinary preparations; biopharmaceuticals; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; pharmaceutical preparations and drugs for the treatment of rare and specialist diseases and conditions; pharmaceutical preparations and drugs for the treatment of orphan diseases; pharmaceutical preparations and drugs for the treatment of respiratory disorders; pharmaceutical preparations and drugs for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical preparations and drugs for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); pharmaceutical preparations and drugs namely bronchodilators and anti-asthma preparations; pharmaceutical preparations and drugs for the treatment of osteogenesis imperfecta (OI) (brittle bone syndrome); pharmaceutical preparations and drugs to improve bone density and treat bone weakness; pharmaceutical preparations and drugs for the treatment of bone-related diseases; pharmaceutical preparations and drugs for the treatment of bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength; pharmaceutical preparations and drugs for the treatment of diseases or disorders associated with collagen mutations; pharmaceutical preparations and drugs for the treatment of obesity; pharmaceutical preparations and drugs for normalising testosterone levels; pharmaceutical preparations and drugs namely aromatase inhibitors (AIs); pharmaceutical preparations and drugs for treating hypogonadotrophic hypogonadism (HH); antibiotics; pharmaceutical preparations and drugs for the treatment of diseases mediated by α-1 antitrypsin deficiency (AATD); pharmaceutical preparations and drugs for the treatment of respiratory diseases; pharmaceutical preparations and drugs for the treatment or prophylaxis of inflammatory diseases and conditions; pharmaceutical preparations and drugs for the treatment or prevention of a symptom or complication attributable of a SARS-COV infection; pharmaceutical preparations and drugs for the treatment of COVID-19; pharmaceutical preparations and drugs for the treatment or prevention of fibrosis; pharmaceutical preparations and drugs for the treatment or prevention of graft rejection; pharmaceutical preparations and drugs for the treatment or prevention of graft versus host disease (GVHD); pharmaceutical preparations and drugs for the treatment or prevention of bronchiolitis obliterans syndrome (BOS); pharmaceutical preparations and drugs for the treatment of cancer; pharmaceutical preparations and drugs for the treatment of checkpoint inhibitor naïve cancer; pharmaceutical preparations and drugs for the treatment of cervical cancer; pharmaceutical preparations and drugs for the treatment of breast cancer; pharmaceutical preparations and drugs for the treatment of ovarian cancer; pharmaceutical preparations and drugs for the treatment of clear cell ovarian cancer; pharmaceutical preparations and drugs for the treatment of sarcoma; pharmaceutical preparations and drugs for the treatment of soft tissue sarcoma; pharmaceutical preparations and drugs for the treatment of de-differentiated liposarcoma sarcoma; pharmaceutical preparations and drugs for the treatment of germ cell tumours; pharmaceutical preparations and drugs for the treatment of testicular germ cell tumours; pharmaceutical preparations and drugs for the treatment of uveal melanomas; pharmaceutical preparations and drugs for the treatment of cancers with a high tumour mutational burden (TMB); pharmaceutical preparations and drugs for the treatment of microsatellite stable cancer; pharmaceutical preparations and drugs for the treatment of endometrial cancer; pharmaceutical preparations and drugs for the treatment of PVR positive cancer; pharmaceutical preparations and drugs for the treatment of TIGIT positive cancer; pharmaceutical preparations and drugs for the treatment of PD-L1 negative cancer; pharmaceutical preparations and drugs for the treatment of CD226 positive cancer; pharmaceutical preparations and drugs for the treatment of CD8 positive cancer; pharmaceutical preparations and drugs for the treatment of cancer involving reducing Tregs and promoting myeloid cell activation.

Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and pharmaceutical research services; scientific research for medical purposes; research, inspection, testing, development and evaluation in the field of medicine and disease; research, inspection, testing, development and evaluation of pharmaceutical and veterinary preparations, products and drugs, sanitary preparations for medical purposes, and dietetic food and substances; clinical trials; information, advisory and consultancy services relating to all the aforesaid services.